Significant Factors of Clinical Outcomes With Olaparib in Patients With Ovarian Cancer

July 30, 2015

Saeed Rafii, MD, PhD, MRCP, medical director, Sarah Cannon Research Institute, discusses the significant factors of clinical outcomes with olaparib in patients who have ovarian cancer.

Rafii urges community oncologists to consider factors, beyond platinum-sensitive and platinum-resistant disease, that may predict responses to olaparib. Patients who have platinum-resistant disease may not be resistant to the drug because the time elapsed since the last platinum agent plays a major role as well. So far, Rafii and his team have observed that olaparib is generally well tolerable.

Saeed Rafii, MD, PhD, MRCP, medical director, Sarah Cannon Research Institute, discusses the significant factors of clinical outcomes with olaparib in patients who have ovarian cancer.